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Abstract
Background: Some patients with inflammatory bowel disease (IBD) do not respond to infliximab (IFX) therapy. 
Gene expression studies revealed genes that may help to predict non-responding IBD patients. Our purpose was to 
validate the discriminating power of published genes.
Methods: Microarray datasets of IBD patients responding or non-responding to IFX were downloaded from 
GEO database (‘transcriptomic arm’). Published genes discriminating responding and non-responding patients were 
identified in PubMed (‘biomarker arm’). Using ROC-analysis, the discriminating performance of genes in ‘biomarker 
arm’ were re-tested in each datasets of ‘transcriptomic arm’. We also performed an independent analysis of colon 
biopsy datasets to identify novel discriminating genes. 
Results: The transcriptomic arm of four GEO datasets (3 and 1 from colon biopsies and blood cells, respectively) 
included 99 patients (of those, 59 and 40 were IFX responder and non-responder, respectively). Of the 65 candidate 
genes reported in biopsy specimens 25 genes discriminated significantly (p<0.05) infliximab responders and non-
responders in the three biopsy datasets consistently. Of the 39 candidate genes reported in peripheral blood 9 genes 
provided significant discrimination after re-testing. Independent analysis of three biopsy datasets identified the top 
five genes. Three genes (IL13RA2, PTGS2 and WNT5A) were highly effective discriminator in each analysis. 
Conclusion: This analysis identified IL13RA2, PTGS2 and WNT5A, three genes in colonic tissues of IBD 
patients as suitable to discrimination between patients responding and non-responding to IFX therapy. These genes 
encode proteins implicated in intestinal pathology; the high expression in non-responding patients may indicate 
important targets in IBD therapy.
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Introduction
Infliximab therapy controls effectively the signs and symptoms 
of inflammatory bowel disease (IBD) in the majority of patients who 
fail to respond conventional therapy. About 40% of IBD patients, 
however, are not responding and are exposed to risks of IFX therapy 
without clinical benefits [1]. Identification of non-responding patients 
before the therapy is, therefore, a big challenge for clinicians. Clinical 
factors determining pharmacokinetics [2] such as baseline laboratory 
data, medicinal history, smoking, dosing schedules are implicated 
in therapeutic failure. However, patients with comparable clinical 
characteristics still differ largely in term of their responsiveness to IFX 
therapy. Therefore, biomarkers are needed to classify IBD patients 
whether they are candidate or not to IFX treatment. 
Biomarkers may vary in term of their nature, physiologic function 
and the sample of origin. While antibodies against IFX are associated 
with loss of response [3], they are not suitable to predict response 
in IFX-naive patients. Recently, in addition to routine laboratory 
indicators and immune markers [4] much research activity focused on 
the measurement of gene expression values in colon biopsy samples 
and peripheral blood to predict the individual response to IFX in IFX-
naive IBD patients. However, study designs including methods used 
to determine gene expression and patient populations to be enrolled 
were quite heterogeneous. In addition, the majority of these studies 
investigated some specific elements or pathways of disease pathogenesis 
and did not analyze the gene expression patterns as a whole. Therefore, 
the information originated from these studies is unavoidably skewed to 
these factors and may ignore important detail beyond the scope of that 
research. These limitations make the comparison and validation of the 
individual study results quite difficult.
The availability of recent gene expression microarray data obtained 
in IBD groups later responding and non-responding to IFX therapy 
provides an opportunity to re-analyze how the published genes would 
perform in another IBD population. 
In this study we cross-validated published data with GEO datasets. 
We also analyzed whether biomarkers identified in blood or biopsy 
samples reflect gene expression patterns in biopsies and peripheral 
blood mononuclear cells, respectively. As a result of this work we 
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identified genes that were consistently suitable to discriminate between 
IBD patients responding and non-responding to IFX therapy in all 
analyzed datasets of colon biopsy specimens. 
Materials and Methods
Literature search 
We have set up the present meta-analysis according to "Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses" guidelines 
published in 2009 (PRISMA)[5]. We used a pipeline requiring for both 
the markers to be validated and the data to be used for validation to be 
identified by a search of available publications and datasets. The design 
for cross-validation process (including identification of transcriptome 
datasets and published biomarkers) is presented in Figure 1.
Construction of GEO-based microarray database: the 
transcriptome arm
We have searched GEO (http://www.ncbi.nlm.nih.gov/gds) using 
the keywords "infliximab" and "response" to identify transcriptomic 
datasets publishing response data against infliximab treatment. Only 
datasets including at least five patients for each included cohort 
(responder and non-responder) were considered. Patients receiving 
placebo were also excluded from the analysis. The series matrix file for 
each eligible dataset was downloaded and subsequently each dataset 
was processed separately.
Genetic biomarkers of IFX responsiveness: the ‘biomarker 
arm’
A search was performed in Pubmed using combinations of the 
keywords ”infliximab”, ”response”, ”marker” and ”gene expression”. 
Only publications in English language were considered. Repeated 
publications were identified and excluded so that each gene was included 
just once in the final database. In addition, only studies publishing 
gene expression biomarkers for inflammatory bowel disease, Crohn’s 
disease and ulcerative colitis were included. We also recorded whether 
the biomarker relates to a gene determined in blood or a biopsy sample. 
The unique gene symbols and names were identified for each gene by 
querying the online repository of the HUGO Gene Nomenclature 
Committee (http://www.genenames.org). 
Statistical analyses
Receiver Operating Characteristics (ROC) analysis was performed 
in the R statistical environment (http://www.r-project.org) using 
Biobase Bioconductor libraries (http://www.bioconductor.org/). In 
a ROC analysis the true positive rate (=sensitivity of the marker) is 
compared to the false positive rate (=100-specificity of the marker) 
for each available cut-off point of a parameter. Thus, each value of the 
ROC curve represents a sensitivity/specificity pair corresponding to a 
particular decision threshold. Then, area under the ROC curve (AUC) 
is computed to measure of how well this parameter can distinguish 
between the two diagnostic groups (responder/nonresponder). The 
AUC value of a perfect biomarker is 1.0.
RECEIVER OPERATING 
CHARACTERISTIC (ROC)
Ulcerative colitis,
patient n=79
Crohn’s disease,
patient n=20
Dataset Responder Nonresponder
GSE12251 (UC) 12 11
GSE16879 (UC) 8 16
GSE23597 (UC) 25 7
GSE42296 (CD) 14 6
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GEO search: ”inﬂiximab ” + 
”response”
Available series,
dataset n=13
Inﬂammatory bowel 
diseases, n=4
PubMed search: ”inﬂiximab”+ ”response” + 
”marker” + ”gene expression”
Re-publication of previous 
marker, n=31
No marker published, n=98 Not IBD
(rheumatoid arthritis 
n=48; psoriasis n=23; 
ankylosing spondylitis 
n=19, other n=45)
Inﬂammatory bowel 
diseases, n=28
Genes in these 
studies, n=24
All available publications, 
n=292
Ulcerative colitis,
n=6
Crohn’s disease,
n=13
IBD,
n=9
Genes in these 
studies, n=63
Genes in these 
studies, n=52
BIOMARKER ARMTRANSCRIPTOMIC ARM
Other disease, n=9 
(RA, JIA, depression)
Measured in at least one transcriptomic study, n=104
Blood-based markers, n=39 Biopsy-based markers, n=65
Figure 1: A flow diagram depicting the exploration of infliximab therapy response biomarker candidates in the published scientific literature and the search 
for transcriptomic datasets in GEO (www.ncbi.nlm.nih.gov/geo/‎) according to the PRISMA guidelines. (UC: Ulcerative Colitis, IBD: Inflammatory Bowel 
Disease, CD: Crohn’s Disease, JIA: Juvenile Idiopathic Arthritis, HUGO: Human Genome Organization Gene Nomenclature Committee)
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We also set up an R function to enable instant reproduction of 
all of the results published in our present study. An R script for ROC 
analysis was also added to the supplemental material (Supplemental 
R script 1.R) with an additional input file needed for designation of 
the samples into responder and non-responder cohorts-these data 
were originally published in the series matrix files in GEO, but could 
not be downloaded in an automated way (Supplemental Table 1). The 
ROC_stats function in the supplemented script calculates the p-values 
that test the null hypothesis that the area AUC really equals 0.5. First, 
the script calculates the standard error of our null hypothesis from 
which the function derives the z-score. Finally, the p-value is calculated 
by the transformation of the z-score using the normal distribution. In 
addition, the function performs downloading and parsing for each of 
the original series matrix files using the GEOquery package (http://
watson.nci.nih.gov/~sdavis/), therefore, there is no need to include 
these in the supplemental material. This new ROC analysis script 
not only enables the user to validate the results of present study, but 
also provides an easy to use tool for independent validation of new 
biomarker candidates. 
With this approach, we re-tested the discrimination performance 
of each of the 104 published genes in the 4 GEO datasets. Statistical 
significance was set at p<0.05 and the genes had to reach statistical 
significance using the average p value across all datasets. 
An independent analysis of GEO datasets was also performed using 
the same statistical approach.
Results
Identification of transcriptomic databases
The database search in GEO resulted in all together 13 datasets, 
of which four datasets were related to IBD. Three and one GEO 
dataset were originated from colon biopsies and blood mononuclear 
cells (PBMC), respectively. These were related to 59 and 40 IFX 
responder and non-responder patients, respectively. Table 1 presents 
the characteristics of these 4 datasets; clinical characteristics for each 
patient are listed in Supplemental Table 2. The entire database contains 
20,168 genes–one should note, however, that some inconsistencies 
regarding gene lists measured in individual datasets exist. Genes 
originated from biomarker studies were verified by each of the four 
independent datasets. 
Biomarkers
We identified 292 publications investigating candidate biomarkers 
of non-responsiveness to IFX therapy. Thirty-one papers repeatedly 
tested biomarkers of previous studies, while 98 studies investigated 
biomarkers other than gene expression. Of the remaining 163 
publications, 28 studies enrolled IBD patients. In these studies a total of 
139 genes were tested as possible biomarkers of IFX responsiveness. Of 
these, 104 were present in at least one of the 4 GEO datasets (Figure 1). 
Published biomarkers of response to infliximab therapy
To avoid batch effects, the datasets were not combined into one 
set. Instead, we performed the entire analysis in each of the datasets. 
Then, 65 and 39 genetic biomarkers identified in biopsy samples and 
blood were related to GEO datasets of biopsy samples and PBMC. The 
complete results of analysis for each of the 104 candidate genes within 
each of the four datasets and the link to the original publication in 
PubMed are listed in Supplemental Table 3. 
Of the 65 candidate genes reported as possible biomarker in 
biopsy specimens just 25 genes discriminated significantly (p<0.05) 
infliximab responders and non-responders in the three biopsy datasets 
consistently. The discriminative power of these biomarkers is listed in 
Table 2A in term of ROC AUC (area under the curve) values. Of note, 
just three biomarkers (S100A8, SELP and CD86) were significant also 
in PBMC dataset. 
Of the 39 candidate genes reported as possible biomarker in 
peripheral blood just 9 genes in PBMC datasets provided significant 
discrimination (p<0.05) between infliximab responders and non-
responders. The discriminative power of these biomarkers is listed in 
Table 2B in term of ROC AUC values; just three biomarker (WARS, 
MAP1LC3B and ODC1) were significant also in biopsies.
Analysis of datasets irrespectively of published results
The complete results of analysis including AUC values and p values 
for all available 20,168 genes in each of the four datasets is presented as 
Supplemental Table 4. In order to identify the most robust markers, we 
considered only those markers which were significant across all three 
independent analyses of colon biopsy samples and with the average of 
ROC values. The top five of these markers are listed in Table 3; of those, 
three (IL13RA2, PTGS2 and WNT5A) were also identified in earlier 
studies. 
Discussion
The discrimination of IBD patients as possible responders and non-
responders before the initiation of IFX therapy is a still unmet clinical 
need. Previous attempts to predict therapeutic response identified 
several genes in colon biopsy samples and peripheral blood. 
Before one would start to investigate clinical usefulness of biomarker 
cited as predictive for therapeutic response in a larger population, the 
published data are worth to be re-validated in independent cohorts. In 
our study the cross-validation of the discriminating biomarkers was 
performed with ROC analysis. ROC AUC curve and associated p values 
were generated using an R-script (available as supplemental material). 
With this approach we demonstrated that merely 17 and 23 per cent of 
published biomarkers provided consistently significant discrimination 
between responding and non-responding patients in transcriptomic 
datasets of the same kind of sample (colon and PBMC, respectively). 
Of note, these biomarkers were not overlapping: biomarkers identified 
in colon biopsy samples were not identical to those in peripheral blood. 
Therefore, datasets of PBMC and biopsy samples are not comparable 
and their information content cannot be pooled. 
Additionally, to confirm the possible relevance of some published 
genes, we also performed a de novo analysis on biopsy datasets. Of 
the top five genes we identified as very efficient discriminators in 
microarray datasets, two genes were novel, while three genes (IL13RA2, 
PTGS2 and WNT5A) published earlier were validated in our study. All 
of these genes exhibited significantly increased expression in colon 
biopsy samples of IBD patients not responding to IFX therapy. (We 
should note, however, that the prediction would be further improved if 
instead of single genes combinations of gene expression levels would be 
Dataset n Platform Tissue Reference
GSE16879 24 GPL570 colon biopsy [23]
GSE12251 23 GPL570 colon biopsy [24]
GSE23597 32 GPL570 colon biopsy [25]
GSE42296 20 GPL6244 PBMC [26]
Table 1: Summary of the GEO datasets included in the construction of the 
transcriptomic database for the meta-analysis of predictive power for infliximab 
therapy response.
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Original study GSE12251COLON BIOPSY
GSE16879
COLON BIOPSY
GSE23597
COLON BIOPSY
GSE42296
PBMC
Symbol Full name Disease n Ref AUC p-value AUC p-value AUC p-value AUC p-value
WNT5A wingless-type MMTV integration site 
family, member 5A CU 46 [24] 0.95* 1.00E-10* 0.92 4.70E-13 0.77 8.1E-03 0.59 0.17
CSF3 colony stimulating factor 3 IBD 16 [27] 0.89 8.30E-10 0.84 1.30E-05 0.81 2.77 E-03 0.58 0.19
PTGS2 prostaglandin-endoperoxide synthase 
2 IBD 16 [27] 0.97 <1E-16 0.87 5.20E-07 0.83 1.11 E-04 0.61 0.12
TNF tumor necrosis factor IBD 16 [27] 0.78 2.70E-03 0.72 0.02 0.82 3.37 E-04 0.63 0.08
G0S2 G0/G1switch 2 CD 37 [28] 0.99 <1E-16 0.85 8.71E-05 0.80 1.97 E-04 0.59 0.17
S100A8 S100 calcium binding protein A8 CD 37 [28] 0.89 1.30E-09 0.84 7.60E-05 0.85 1.58 E-06 0.66 0.03
IL6 interleukin 6 IBD 16 [27] 0.92 1.49E-11 0.87 5.35E-07 0.81 1.62 E-04 0.57 0.22
IL8 interleukin 8 IBD 16 [27] 0.95 <1E-16 0.8 8.51E-04 0.75 4.80 E-03 0.51 0.45
CXCL6 chemokine (C-X-C motif) ligand 6 CU 46 [24] 0.73* 0.018* 0.88 4.10E-07 0.70 0.044 0.62 0.10
SELP selectin P IBD 16 [27] 0.9 2.70E-10 0.68 0.077 0.85 1.83 E-05 0.73 0.003
ACSL4 acyl-CoA synthetase long-chain family 
member 4 CU 46 [24] 0.75* 0.041* 0.89 5.60E-09 0.84 1.30E-05 0.64 0.06
CD80 CD80 molecule IBD 16 [27] 0.68 0.06 0.78 0.0020 0.69 0.07 0.61 0.13
CD86 CD86 molecule IBD 16 [27] 0.76 0.024 0.75 0.012 0.87 7.80E-07 0.78 2.40E-04
CXCL10 chemokine (C-X-C motif) ligand 10 IBD 16 [27] 0.68 0.08 0.71 0.03 0.8 0.0004 0.58 0.21
CSF2
colony stimulating factor 2 
(granulocyte-macrophage) IBD 16 [27] 0.69 0.1 0.8 0.001 0.79 0.0007 0.54 0.32
IGFBP5
insulin-like growth factor binding 
protein 5 CU 46 [24] 0.72* 0.07* 0.77 0.005 0.91 2.91E-13 0.57 0.22
IL10 interleukin 10 CU 37 [28] 0.72 0.038 0.74 0.011 0.87 4.20E-06 0.61 0.12
IL13RA2 interleukin 13 receptor, alpha 2 CU 46 [24] 0.78* 0.043* 0.9 1.30E-09 0.95 <1E-16 0.64 0.058
IL1A interleukin 1, alpha IBD 16 [27] 0.73 0.07 0.94 <1E-16 0.77 0.003869 0.62 0.09
IL1B interleukin 1, beta IBD 16 [27] 0.72 0.15 0.97 <1E-16 0.81 0.0003 0.5 0.5
LPHN2 latrophilin 2 CU 46 [24] 0.72* 0.06* 0.78 0.006 0.88 1.17E-08 0.58 0.20
PTPRC
protein tyrosine phosphatase, receptor 
type, C IBD 16 [27] 0.69 0.047 0.7 0.039 0.78 2.00E-03 0.63 0.07
RGS2
regulator of G-protein signaling 2, 
24kDa CU 46 [24] 0.71* 0.05* 0.9 2.79E-10 0.69 0.04 0.65 0.05
S100A9 S100 calcium binding protein A9 CD 37 [28] 0.77 0.042 0.95 <1E-16 0.88 4.40E-05 0.62 0.09
SELE selectin E IBD 16 [27] 0.73 0.09 0.91 4.74E-10 0.84 0.0003 0.56 0.28
Gene Original study GSE42296in PBMC Sample biopsy datasets (n=3)
Symbol Full name Disease Type of sample n Ref AUC p-value Average AUC Average p value
C1R complement component 1, r subcomponent IBD serum 18 [29] 0.75 1.50E-03 0.72 0.06
MAP1LC3B microtubule-associated protein 1 light chain 3 beta CD peripheral 20 [26] 0.74 2.12E-04 0.69 0.02
WARS tryptophanyl-tRNA synthetase CD peripheral 20 [26] 0.71 7.10E-03 0.78 0.01
APOA4 Apolipoprotein A-IV IBD serum 18 [29] 0.7 1.24E-03 0.58 0.26
CA2 carbonic anhydrase II CD peripheral 20 [26] 0.69 1.40E-03 0.65 0.11
ODC1 ornithine decarboxylase 1 CD peripheral 20 [26] 0.69 1.76E-03 0.76 0.006
BMP6 bone morphogenetic protein 6 CD peripheral 20 [26] 0.69 1.82E-03 0.53 0.41
PBX1 pre-B-cell leukemia homeobox 1 CD peripheral 20 [26] 0.68 1.98E-03 0.64 0.12
CYP1B1 cytochrome P450, family 1, subfamily B, polypeptide 1 CD peripheral 20 [26] 0.65 4.64E-03 0.56 0.32
A
B
C
Source: biopsy Source: blood
All published markers 65 39
Of these: validation in same tissue is OK 25 9
Of these: validation in different tissue is OK 3 3
Table 2: Detailed results for previously published biomarker candidates including characteristics of the original studies describing the marker as well as performance of the 
gene to discriminate responder and non-responder patients after infliximab therapy in each available dataset. Biomarkers identified in colon biopsy specimens (A) include 
genes with a p value <0.05 as the average of the three biopsy-based dataset is listed. Biomarkers identified in blood samples (B) and number of genes with a consistent 
discriminator performance in each dataset of the same type of sample (C). Ref #17 has more patients as in Table 1 because in the original study additional samples were 
included in the discovery set. *Genes identified in GSE12251 were also described in the paper where GSE12251 was published–these are included because their average 
p-value is significant in the two other datasets.
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studies, Wnt5a (a noncanonical Wnt ligand) potentiated colonic 
crypt regeneration after tissue injury [17]. On the other hand, high 
Wnt5a levels were associated with poor prognosis in colorectal cancer 
patients and promoted human colon cancer cell migration in animals 
[18]. The contribution of Wnt5a to polyp formation in colon was also 
suggested [19]. Wnt5a is also involved in the induction of epithelial-
to-mesenchymal transition [20], a common phenomenon in chronic 
inflammatory conditions. 
Data suggest that the relative absence of an endogenous Wnt-
inhibitor in colonic myofibroblasts (and, consequently, the increase 
of Wnt levels in crypts) is associated with an increased risk of cancer 
in ulcerative colitis [21]. Although there are no data available whether 
IBD patients non-responding to IFX therapy are at an increased risk 
for colon cancer, an animal study indicated that IBD animals treated 
with IFX are protected from colon cancer [22-29]. Therefore, one may 
also speculate that patients having high Wnt5a gene expression may 
be subjected to IFX non-responsiveness and, also, are at a higher risk 
of cancer. These data together are suggestive that the causative role of 
Wnt5a in resistance to IFX therapy may be worth to be investigated 
further. 
The major limitation of our in silico analysis is the verification of 
our results in independent datasets. However, the lack of an available 
biobank with IFX responding and non-responding patients’ biopsy 
specimens prevented the prompt investigation of this issue; several 
years are required to complete this task. Therefore, this analysis should 
be regarded rather as a hypothesis-generating one.
In conclusion, our analysis revealed that IL13RA2, PTGS2 and 
WNT5A, genes expressed in colonic tissues of IBD patients are 
suitable to discriminate patients responding and non-responding to 
IFX therapy. As all three genes encode proteins that are implicated in 
intestinal homeostasis and pathology; the difference in their expression 
in responding and non-responding patients may indicate important 
diagnostic targets in IBD therapy.
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used; however, the relatively small sample size would not allow to make 
established conclusions.) 
In addition to use as biomarkers to discriminate between IBD 
patients responding and non-responding to IFX treatment these genes 
may provide novel perspectives in IBD pharmacotherapy. While the 
major limitation of our in silico study is the absence of protein levels, 
one may assume that transcriptome is representative for the proteome. 
Therefore, one may speculate that proteins encoded by these genes as 
PTGS2, IL13RA and Wnt5a may predict and, theoretically, contribute 
to the responsiveness to IFX in IBD.
PTGS2 is the gene that encodes the enzyme prostaglandin-
endoperoxide synthase also called as cyclooxygenase-2 (COX-2) the 
enzyme is responsible for the production of prostaglandin H2, an 
inflammatory mediator from arachinodic acid. Previous observations 
indicate higher than normal PTGS2 expression in colonic epithelial 
cells in IBS [6] and that PTGS2 expression is associated with disease 
activity [7]. In addition to these data our analysis indicates that patients 
do not responding to IFX therapy may exhibit even higher PTGS 
expression than those with appropriate response. This finding is in line 
with the demonstrated contribution of inflammatory prostaglandins to 
the pathogenesis of IBD. 
On the other hand, COX-2 derived prostaglandins also have a role in 
mucosal defense in the small intestine and colon [8]. Hence, inhibition 
of COX-2 is a double-edged sword as it is reflected by controversial 
results of controlled trials and experimental colitis models with COX-2 
inhibitors [9]. Administration of COX-2 inhibitors was associated with 
the cited as a possible contributor to the integrity of intestinal mucosa, 
in the healing of gastrointestinal ulcers and in the modulation of IBD 
[10], but exacerbation of IBD was also reported in several studies with 
COX-2 inhibition [11]. 
Interleukin (IL)-13 is an important regulator of epithelial apoptosis 
in immune mediated disorders [12]. It plays a role in inflammation, 
mucus production, tissue remodeling, and fibrosis [13]. Disturbed 
IL-13-expression may play a role in immune dysregulation [14]. 
IL-13 signaling is mediated by the type-2 IL-4 receptor. The IL-13 
receptor alpha 2 (IL13RA2) inhibits the activity of IL-13; IL-13Ralpha2 
contributes to the down-regulation of a chronic and pathogenic Th2-
mediated immune response [15]. These literary data support the results 
of our analysis indicating the association of an abnormal IL13RA2 
expression with infliximab unresponsiveness.
Literary data on Wnt5a gene product are also promising. Members 
of Wnt family are glycoproteins actively secreted by cells and along with 
other pathways (e.g. FGF, Notch, BMP, and Hedgehog signalization) 
they contribute to intestinal stem cell biology, the maintenance of 
homeostasis, and, in case of malfunctioning, to pathological conditions 
including inflammation and cancer [16]. Regarding Wnt5a, several 
possible functions in gastrointestinal tract were reported. In animal 
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Symbol Full name Average AUC AUC P-Value AUC P-Value AUC P-Value
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Table 3: Top five genes ranked by AUC with consistently significant predictive values in all the 3 GEO datasets of colon biopsy samples.  Bold: genes overlapping 
to Table 2.
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